Due to poor air quality, the Academy San Francisco offices will be closed Friday, Nov. 16. 

    ASRS 2016

    In this interview from ASRS 2016, Dr. Rahul N.  Khurana  discusses results from the phase 4 NEWTON trial,  which switched patients with central retinal vein occlusionsCRVO)  and recurrent  macular edema  from  fixed interval bevacizumab or ranibizumab injections to treat-and-extend aflibercept. After intervention, 19/20 patients were able to increase their treatment interval by an average of 26 days, corresponding to approximately 4 fewer injections a year.  Dr.  Khurana states that aflibercept may be a more durable anti-VEGFagent for eyes with CRVO or those  requiring  chronic therapy.